Streetbeat News

Stock Prices

ARCC

The article highlights four strong buy stocks with dividends of 7% or higher, appealing to investors seeking dependable passive income and solid total returns.

Portfolio Pulse from

March 07, 2025 | 12:00 pm

TMDX

A class action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) for potential securities law violations. Investors who suffered losses are encouraged to join the lawsuit by April 15, 2025.

Portfolio Pulse from

March 07, 2025 | 12:00 pm

TTD

The Trade Desk stock has fallen by 48% in 2025, presenting a potential buying opportunity for long-term investors.

Portfolio Pulse from

March 07, 2025 | 11:45 am

ROL

Rollins, a leading pest control services company, has achieved a remarkable 12,700% total return since 2000, making it a 128-bagger. This highlights its strong dividend growth and potential for investors.

Portfolio Pulse from

March 07, 2025 | 11:45 am

TSLA

The article suggests buying Tesla stock in 2025 but selling in 2026 due to concerns over Elon Musk's influence on regulatory agencies amidst ongoing probes and lawsuits.

Portfolio Pulse from

March 07, 2025 | 11:45 am

IOT

Samsara's fiscal 2026 report indicates slowing growth but improved free cash flow and a strong, debt-free balance sheet. The stock, trading at $40 per share, is seen as attractive but not a homerun. Samsara targets large enterprises with AI-driven fleet management solutions, offering growth potential.

Portfolio Pulse from

March 07, 2025 | 11:45 am

SMCI

Super Micro's stock is experiencing a decline due to mixed signals from AI-related earnings reports by Broadcom and HP Enterprise.

Portfolio Pulse from

March 07, 2025 | 11:30 am

HIMS

Hims & Hers Health (HIMS) has been a strong performer in the healthcare sector, with a 350% increase over five years due to its personalized telehealth services. However, the stock recently dropped by 15.90%, indicating potential challenges ahead.

Portfolio Pulse from

March 07, 2025 | 11:30 am

T

AT&T's dividend yield has decreased to 4.24%, the lowest in at least 5 years, with stagnating dividend growth. Due to CAPEX obligations, debt, and margin pressure, dividend growth is unlikely to resume soon.

Portfolio Pulse from

March 07, 2025 | 11:30 am

BIOA

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA) related to its IPO. Investors with substantial losses have until March 10, 2025, to seek appointment as lead plaintiff.

Portfolio Pulse from

March 07, 2025 | 11:30 am